Table 1.
Baseline characteristics of patients with preexisting DSAs in BENEFIT
| Belatacept MI (n = 10) | Belatacept LI (n = 11) | Cyclosporine (n = 14) | |
|---|---|---|---|
| Mean age, y (SD) | 49.6 (16.9) | 45.0 (7.2) | 43.7 (12.6) |
| Male, n (%) | 3 (30.0) | 3 (27.3) | 6 (42.9) |
| Race | |||
| White | 7 (70.0) | 6 (54.5) | 7 (50.0) |
| Black | 0 (0) | 2 (18.2) | 1 (7.1) |
| Asian | 2 (20.0) | 2 (18.2) | 1 (7.1) |
| Other | 1 (10.0) | 1 (9.1) | 5 (35.7) |
| Region | |||
| North America | 4 (40.0) | 3 (27.3) | 7 (50.0) |
| South America | 2 (20.0) | 3 (27.3) | 1 (7.1) |
| Europe | 3 (30.0) | 3 (27.3) | 4 (28.6) |
| Rest of world | 1 (10.0) | 2 (18.2) | 2 (14.3) |
| Categorized PRA, n (%) | |||
| <20% | 8 (80.0) | 8 (72.7) | 11 (78.6) |
| ≥20% | 2 (20.0) | 3 (27.3) | 2 (14.3) |
| Missinga | 0 (0) | 0 (0) | 1 (7.1) |
| Reported cause of ESRD, n (%) | |||
| Glomerulonephritis | 3 (30.0) | 4 (36.4) | 3 (21.4) |
| Diabetes | 2 (20.0) | 1 (9.1) | 3 (21.4) |
| Polycystic kidneys | 1 (10.0) | 1 (9.1) | 1 (7.1) |
| Congenital, familial, and metabolic | 1 (10.0) | 1 (9.1) | 0 (0) |
| Re‐transplant/graft failure | 0 (0) | 0 (0) | 2 (14.3) |
| Other | 3 (30.0) | 4 (36.4) | 5 (35.7) |
| T‐cell crossmatch–negative | 10 (100.0) | 11 (100.0) | 14 (100.0) |
| Preexisting DSA HLA class specificity, n (%) | |||
| Class I | 7 (70.0) | 7 (63.6) | 9 (64.3) |
| Class II | 2 (20.0) | 3 (27.3) | 4 (28.6) |
| Class I and II | 1 (10.0) | 1 (9.1) | 1 (7.1) |
| Average MFI of DSAs | |||
| Total | 10 689 | 9806 | 7014 |
| Class I‐only | 9292 | 9529 | 6605 |
| Class II‐only | 14 320 | 10 775 | 8042 |
DSA, donor‐specific antibody; ESRD, end‐stage renal disease; LI, less intense; MFI, mean fluorescence intensity; MI, more intense; PRA, panel reactive antibody; SD, standard deviation.
a
On the case report form, investigators had to tick off whether a patient satisfied all eligibility criteria. Although there was space on the form for investigators to provide numerical results for the highest and most recent PRA percentages, they were not required to do so. Thus, the PRA percentage is missing for some study participants.